Latest Affinity Asset Advisors, LLC Stock Portfolio
Affinity Asset Advisors, LLC Performance:
2024 Q3: 8.43%YTD: 19.07%2023: 12.37%
Performance for 2024 Q3 is 8.43%, and YTD is 19.07%, and 2023 is 12.37%.
About Affinity Asset Advisors, LLC and 13F Hedge Fund Stock Holdings
Affinity Asset Advisors, LLC is a hedge fund based in NEW YORK, NY. On 29-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $237.6 Millions. In it's latest 13F Holdings report, Affinity Asset Advisors, LLC reported an equity portfolio of $732.8 Millions as of 30 Sep, 2024.
The top stock holdings of Affinity Asset Advisors, LLC are XENE, , NUVL. The fund has invested 6.2% of it's portfolio in XENON PHARMACEUTICALS INC and 5.3% of portfolio in APOGEE THERAPEUTICS INC.
The fund managers got completely rid off MORPHIC HLDG INC (MORF), ELEVATION ONCOLOGY INC (ELEV) and HILLEVAX INC (HLVX) stocks. They significantly reduced their stock positions in PROMIS NEUROSCIENCES INC (PMN), CELLDEX THERAPEUTICS INC NEW (CLDX) and INARI MED INC (NARI). Affinity Asset Advisors, LLC opened new stock positions in ORUKA THERAPEUTICS INC, ARVINAS INC (ARVN) and TERNS PHARMACEUTICALS INC (TERN). The fund showed a lot of confidence in some stocks as they added substantially to ARROWHEAD PHARMACEUTICALS IN (ARWR), WAVE LIFE SCIENCES LTD (WVE) and VIRIDIAN THERAPEUTICS INC (VRDN).
The top stock holdings of Affinity Asset Advisors, LLC are XENE, , NUVL. The fund has invested 6.2% of it's portfolio in XENON PHARMACEUTICALS INC and 5.3% of portfolio in APOGEE THERAPEUTICS INC.
The fund managers got completely rid off MORPHIC HLDG INC (MORF), ELEVATION ONCOLOGY INC (ELEV) and HILLEVAX INC (HLVX) stocks. They significantly reduced their stock positions in PROMIS NEUROSCIENCES INC (PMN), CELLDEX THERAPEUTICS INC NEW (CLDX) and INARI MED INC (NARI). Affinity Asset Advisors, LLC opened new stock positions in ORUKA THERAPEUTICS INC, ARVINAS INC (ARVN) and TERNS PHARMACEUTICALS INC (TERN). The fund showed a lot of confidence in some stocks as they added substantially to ARROWHEAD PHARMACEUTICALS IN (ARWR), WAVE LIFE SCIENCES LTD (WVE) and VIRIDIAN THERAPEUTICS INC (VRDN).
Affinity Asset Advisors, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Affinity Asset Advisors, LLC made a return of 8.43% in the last quarter. In trailing 12 months, it's portfolio return was 49.31%.
New Buys
| Ticker | $ Bought |
|---|---|
| oruka therapeutics inc | 8,574,480 |
| arvinas inc | 5,541,750 |
| terns pharmaceuticals inc | 5,004,000 |
| travere therapeutics inc | 4,320,000 |
| soleno therapeutics inc | 1,262,250 |
| verastem inc | 1,196,000 |
| biomarin pharmaceutical inc | 1,054,350 |
| repare therapeutics inc | 596,327 |
New stocks bought by Affinity Asset Advisors, LLC
Additions
Additions to existing portfolio by Affinity Asset Advisors, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| promis neurosciences inc | -88.48 |
| celldex therapeutics inc new | -73.71 |
| inari med inc | -70.00 |
| beigene ltd | -68.18 |
| insmed inc | -60.00 |
| savara inc | -54.75 |
| mirum pharmaceuticals inc | -51.61 |
| roivant sciences ltd | -42.66 |
Affinity Asset Advisors, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| bridgebio pharma inc | -17,256,800 |
| alnylam pharmaceuticals inc | -16,200,000 |
| elevation oncology inc | -3,965,830 |
| mersana therapeutics inc | -1,541,670 |
| black diamond therapeutics i | -3,029,000 |
| adc therapeutics sa | -1,500,190 |
| olema pharmaceuticals inc | -2,975,500 |
| hillevax inc | -3,844,320 |
Affinity Asset Advisors, LLC got rid off the above stocks
Sector Distribution
Affinity Asset Advisors, LLC has about 87.9% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 87.9 |
| Others | 12.1 |
Market Cap. Distribution
Affinity Asset Advisors, LLC has about 6.3% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 46.9 |
| SMALL-CAP | 25.8 |
| UNALLOCATED | 16.4 |
| LARGE-CAP | 5 |
| MICRO-CAP | 3.5 |
| MEGA-CAP | 1.3 |
| NANO-CAP | 1.2 |
Stocks belong to which Index?
About 54% of the stocks held by Affinity Asset Advisors, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 54 |
| Others | 46 |
Affinity Asset Advisors, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Affinity Asset Advisors, LLC
Affinity Asset Advisors, LLC has 73 stocks in it's portfolio. About 39% of the portfolio is in top 10 stocks. MDGL proved to be the most loss making stock for the portfolio. ACLX was the most profitable stock for Affinity Asset Advisors, LLC last quarter.
Last Reported on: 13 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AADI | aadi bioscience inc | 0.01 | 47,019 | 96,859 | new | |||
| ABIO | arca biopharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ACLX | arcellx inc | 4.56 | 400,000 | 33,404,000 | reduced | -13.04 | ||
| ADCT | adc therapeutics sa | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AGLE | spyre therapeutics inc | 2.00 | 498,420 | 14,658,500 | reduced | -2.92 | ||
| ALKS | alkermes plc | 3.82 | 1,000,000 | 27,990,000 | added | 53.85 | ||
| ALNY | alnylam pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARVN | arvinas inc | 0.76 | 225,000 | 5,541,750 | new | |||
| ARWR | arrowhead pharmaceuticals in | 0.86 | 325,000 | 6,295,250 | added | 550 | ||
| ARYD | arya sciences acqu corp iv | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ATXS | astria therapeutics inc | 1.09 | 725,106 | 7,983,420 | reduced | -25.68 | ||
| AUTL | autolus therapeutics plc | 2.23 | 4,500,000 | 16,335,000 | added | 4.65 | ||
| AVTE | aerovate therapeutics inc | 0.17 | 600,000 | 1,254,000 | added | 200 | ||
| AVTX | avalo therapeutics inc | 0.06 | 45,000 | 425,700 | unchanged | 0.00 | ||
| AXSM | axsome therapeutics inc | 0.98 | 80,000 | 7,189,600 | unchanged | 0.00 | ||
| BBIO | bridgebio pharma inc | 1.04 | 300,000 | 7,638,000 | added | 200 | ||
| BBIO | bridgebio pharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BDTX | black diamond therapeutics i | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BGNE | beigene ltd | 1.07 | 35,000 | 7,857,850 | reduced | -68.18 | ||
| BIL | spdr ser tr | 0.00 | 0.00 | 0.00 | sold off | -100 | ||